A5057014927- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Biomedical and Engineering Education
- Spine and Intervertebral Disc Pathology
- Academic and Historical Perspectives in Psychology
- Traumatic Brain Injury Research
- Cancer-related Molecular Pathways
- Educational Games and Gamification
- Gastric Cancer Management and Outcomes
- Melanoma and MAPK Pathways
- Human Resource Development and Performance Evaluation
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Cancer Mechanisms and Therapy
- Musculoskeletal pain and rehabilitation
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Teaching and Learning Programming
Molecular Medicine Ireland
2024
Royal College of Surgeons in Ireland
2018-2023
Beaumont Hospital
2021
California Polytechnic State University
2018
Richland College
2016
Abstract Background Aberrant PI3K signalling is implicated in trastuzumab resistance HER2-positive gastric cancer (GC). The role of or MEK inhibitors sensitising GCs to overcoming unclear. Methods Using mass spectrometry-based genotyping we analysed 105 hotspot, non-synonymous somatic mutations PIK3CA and ERBB-family ( EGFR , ERBB2 ERBB3 ERBB4 ) genes tumour samples from 69 patients. A panel cell lines (N87, OE19, ESO26, SNU16, KATOIII) were profiled for anti-proliferative response the...
Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 in colorectal cancer (CRC), however single agent therapeutics are often limited by development resistance.We compared anti-proliferative effects combination five CRC cell lines with varying mutational background tested their combinations on total phosphoprotein levels signaling pathway proteins.The was superior to PD0325901. The had synergistic all [CI...
Responses to neoadjuvant chemoradiotherapy for locally advanced rectal cancer are not uniform. The phosphatidylinositol-3 kinase (PI3K) and mitogen-activated protein (MAPK) pathways involved in tumorigenesis treatment resistance many cancers; therefore, targeting these could enhance response chemoradiotherapy. A panel of colorectal (CRC) cell lines (n = 10) with varying PI3K MAPK mutational backgrounds were treated combinations 5-Flourouracil (5-FU), radiation, the inhibitor copanlisib,...
Since 2010, the Cal Poly Computer Science Department has required computing majors to select from a variety of CS0 courses start their academic year. The broad objective course is attract and retain undergraduates that have no prior experience in CS by using authentic problems demonstrate relevance highlight role computers solving "real world" problems. offered thematic "flavors" leverage student's pre-existing interests (e.g. music or art), but all share common goals introducing students...
The CDK4/6 inhibitor Ribociclib has shown limited efficacy as a monotherapy in colorectal cancer (CRC). However, combining with targeted therapies could present viable strategy for treating CRC. This study evaluated the combination of and PI3K Alpelisib across four distinct cell lines representing different mutational statuses (
179 Background: Combinative inhibitors with multiple actions to target downstream effectors are good strategy reduce resistance occurrence. This is a preclinical study evaluate efficacy of Palbociclib (P; CDK4/6 inhibitor) in combination either Gedatolisib (G; P13K/mTOR dual inhibitors) or PD0325901 (PD; MEK 1/2 CRC cell models. Methods: Five lines hot-spots mutations PI3K and MAPK pathways genes used. Cell growth assay used antiproliferative response P, G PD alone combination. RPPA clarify...
Abstract Background: Studies have demonstrated the efficacy of Palbociclib (CDK 4/6 inhibitor), Gedatolisib (PI3K/mTOR dual inhibitor) and PD0325901 (MEK1/2 in colorectal cancer (CRC), however single agent therapeutics are often limited by resistance. The main purpose this vitro study is to comprehensively test two drug combinations [Palbociclib with (P+G) (P+PD)] determine most synergistic combination for clinical development. Methods: We compared anti-proliferative effects both five CRC...